In a multicentre trial involving 20 transplant centres from 10 countries haematopoietic stem cells were obtained either from the bone marrow of 33 sibling donors or from the peripheral blood of 33 such donors after administration of filgrastim (10 g/kg/day). transplant-related mortality until day 100 and leukaemia-free survival at a median of 400 days after BMT or PBPCT showed no significant differences. Administration of filgrastim and leukapheresis in normal donors were feasible and well tolerated. The number of days with restricted activity and of nights spent in hospital was lower in donors of PBPC. Transplantation of PBPC to HLA-identical siblings with early leukaemia resulted in earlier platelet engraftment. The incidence of moderate to severe acute GVHD, transplant-related mortality, and leukaemia-free survival did not show striking differences. Further investigation of allogeneic PBPCT as a substitute for allogeneic BMT is warranted.
The first small series of patients transplanted with allogeneic granulocyte colony-stimulating factor (G-CSF)-mobilised peripheral blood progenitor cells (PBPC) were published in 1995. [1] [2] [3] [4] These studies have led to a surge of allogeneic PBPC transplants (PBPCT) comparable to that seen some years earlier when autologous PBPCT started to replace autologous bone marrow transplantation (BMT). In 1995, 571 allogeneic PBPCT were reported to the European Group for Blood and Marrow Transplantation (EBMT) 5 and in 1996, over 1100 transplants (representing close to a quarter of all allogeneic transplants performed in Europe) used PBPC as the source of hematopoietic stem cells (A Gratwohl, data on file). This massive switch from marrow to blood contrasts with the scarcity of reliable information supporting this change: besides a number of uncontrolled single institution studies only a single small and retrospective matched pair analysis comparing allogeneic PBPCT with BMT has been reported. 6 Randomised trials have not been published. 996 We report the results of the first prospective randomised trial evaluating the feasibility and safety of allogeneic PBPCT in comparison to BMT in patients with early leukaemias.
Patients and methods

Study design
This was a randomised, multicentre trial designed to investigate the feasibility, safety, and outcome of allogeneic PBPCT compared with BMT. Seventy recipients and their HLA-identical sibling donors were enrolled at 20 institutions from 10 countries. The study was approved by the ethics committee of each participating centre and written informed consent was obtained from all donors and recipients. Patients were centrally randomised at the International Institute for Drug Development (id 2 ), Brussels, Belgium, where inclusion and exclusion criteria were checked prior to randomisation. The minimisation method was used to allocate donor and recipient to the BMT or PBPCT arm of the study. This method stratifies randomisation and in this case took into account if the diagnosis was chronic myelogenous leukaemia (CML) or acute leukaemia and if the donor was female and had ever been pregnant. The morphologic subtypes of acute leukaemias and other prognostic factors (ie karyotype, initial WBC, duration of remission for patients grafted in CR2) were not considered for stratification.
Patients
Patients between 18 and 50 years of age and an ECOG performance status of 0-2 were eligible to participate in the study if they had a diagnosis of de novo acute myelogenous leukaemia (AML) or acute lymphoblastic leukaemia (ALL) in first or second remission, or CML in first chronic phase. Patients with inadequate organ function (serum creatinine Ͼ10% above normal, abnormal left ventricular size or function, DLCO Ͻ50%, bilirubin Ͼ2 mg/dl), HIV positivity, and/or a history of splenectomy or splenic irradiation were excluded as were patients who previously had received a BM or PBPC transplant.
Donors
The sibling donors were between 18 and 60 years of age and HLA-identical to the recipient. Exclusion criteria were any of the following: inability to undergo general anaesthesia and bone marrow or PBPC harvest, peripheral venous access deemed impossible at initial examination, positive serology for HIV, hepatitis C or B, or a history of malignant disease or concurrent malignancy.
Harvest procedures
Donors randomised to donate BM had their marrow harvested from both posterior iliac crests under general anaesthesia. A minimum of 2 × 10 8 nucleated cells/kg recipient weight was required for transplantation. Donors randomised to undergo PBPC collection were treated with filgrastim (r-metHuG-CSF) (Amgen, Thousand Oaks, CA, USA) at a dose of 10 g/kg/day subcutaneously for 4 or 5 consecutive days depending on the yield of the first leukapheresis. Leukapheresis was started on day 5 of filgrastim administration using an automated continuous-flow blood cell separator. A minimum of 4 × 10 6 CD34 + cells/kg recipient weight was to be collected. If this goal was met with one leukapheresis the harvest product was stored at 4°C overnight and infused into the patient on the following day (defined as day 0 for the recipient). If the first leukapheresis gave less than 4 × 10 6 CD34 + cells/kg the donor received another filgrastim injection, the first leukapheresis product was stored as described but was infused with a second leukapheresis product collected on the following day (day 0). BM harvests and PBPC collection products were characterised in an identical manner at each participating institution: the total number of nucleated cells (NC), CD34
+ cells (using the HPCA-2-PE antibody; Becton Dickinson, Heidelberg, Germany), T lymphocytes (UCHT-1-FITC antibody, DAKO, Hamburg, Germany), natural killer (NK) cells (Leu-19-PE antibody; Becton Dickinson) as well as the number of colony-forming unitsgranulocyte/macrophage (CFU-GM) were counted. If there was AB0 incompatibility between recipient and donor the red blood cells and/or plasma were separated from the graft prior to transplantation. Other manipulations of the graft (ie cryopreservation, CD34
+ selection) were not allowed.
Conditioning
Conditioning therapy had to be identical for all patients treated at each of the participating institutions and could consist of either total body irradiation (TBI) administered as a single dose у7.5 Gy or fractionated with a total dose у10 Gy in conjunction with cyclophosphamide or etoposide or combinations thereof. Alternatively, busulphan (total dose 16 mg/kg) and cyclophosphamide (200 mg/kg) could be used as a non-TBI containing regimen. BM or PBPC cells were infused via a central venous catheter on day 0 (defined as the day bone marrow would ordinarily have been given).
Prophylaxis and treatment of graft-versus-host disease (GVHD)
GVHD prophylaxis consisted of cyclosporin A (CsA) and methotrexate (MTX). CsA was started on day −1 and stopped on day +180 unless active GVHD required continuation of the drug. CsA was given intravenously until oral administration became feasible; dosing of CsA followed local practice but was monitored by regular measurements of CsA plasma levels. MTX was injected on day +1 (15 mg/m 2 ) and days +3 and +6 (10 mg/m 2 each). If acute GVHD developed intravenous methylprednisolone or oral prednisolone was administered. Further treatment -if necessary -was left to the discretion of the responsible physician. Acute GVHD was graded daily for inpatients and twice weekly thereafter until day +100 according to 997 the Glucksberg criteria; 7 chronic GVHD was classified as described by Shulman et al. 8 
Supportive care and clinical monitoring
All patients received intravenous or subcutaneous filgrastim at a dose of 5 g/kg/day starting 24 h after transplantation of BM or PBPC until absolute neutrophil counts (ANC) of either 1.0 × 10 9 /l for 3 consecutive days or 10 × 10 9 /l for 1 day were reached. Filgrastim was stopped at day 28 regardless of the ANC. Prophylaxis and treatment of infections were left to the discretion of the investigator but needed to follow a standardised plan at each participating centre. Prophylactic administration of gancyclovir was not allowed. Platelet and red blood cell (RBC) transfusions were given according to centre policy.
The patients' history, performance status, vital signs, complete blood count (CBC), and biochemistry were recorded pre-study, at regular intervals during hospitalisation, and at each follow-up visit but at least at 6, 9, 12, 24 and 36 months after transplantation. Bone marrow aspirates were performed pre-study and on days +28, +100 as well as 12, 24 and 36 months after grafting in order to evaluate the remission status and chimeric state of the patient.
Each donor was asked about his medical history and had a physical examination prior to entering the study. Performance status, CBC, biochemistry, and vital signs were documented pre-study, daily during filgrastim administration and leukapheresis, and 30 days after BM or PBPC harvest. All adverse events (definition see below) were recorded. In addition, patients were asked about their donor's well being 100 days, 6, 9, 12, 24 and 36 months after grafting; telephone interviews with the donors were scheduled at the same time intervals.
Study endpoints and definitions
Experience with the administration of G-CSF to normal individuals is limited. Therefore, in the donors all adverse events defined as any new undesirable medical experience or change of an existing condition which occurred during or after treatment whether or not related to filgrastim or leukapheresis were documented and analysed. Adverse events in the donors which required medical intervention (ie blood transfusion, drug treatment) were considered severe. The route of access and the duration of the leukapheresis procedure, the duration of hospitalisation, and the number of days with restriction of regular activities were also recorded.
The safety of the patients enrolled in the study was monitored by evaluating the incidence of severe toxicities which were defined as engraftment failure, acute GVHD of grades III and IV, organ toxicity of grades 3 and 4 according to the Bearman criteria, 9 or death from any cause. Secondary endpoints for the recipient were the time to an unsupported platelet count of 20 or 50 × 10 9 /l (ie the time from transplantation to the first of 3 consecutive days without a platelet transfusion and a platelet count above 20 or 50 × 10 9 /l), the time to an ANC of 0.5 or 1.0 × 10 9 /l, the duration of fever and hospitalisation, the incidence and severity of acute and chronic GVHD, relapse incidence, leukaemiafree survival, and time to death.
Statistical analysis
The primary objective of this study in both donors and recipients was to demonstrate the feasibility and safety of allogeneic PBPCT in comparison to BMT. Secondary endpoints are summarised in the section 'study endpoints and definitions'. Because the study protocol included the possibility of extending the study to a phase III trial comparing the incidence and severity of acute GVHD as primary endpoint we chose to perform no formal tests on the results reported here. Instead, descriptive statistics and estimates of differences for relevant endpoints together with the respective 95% confidence intervals are given to compare allogeneic PBPCT and BMT. Analyses were based on the intention-to-treat principle as far as relevant data were available.
Results
Donors
The median age, sex, parity, and CMV status of all donors entered into this study are summarised in Table 1 . Important differences between donors randomised to bone marrow harvest or PBPC collection were not observed. Thirty-three of 36 PBPC donors and 33 of 34 bone marrow donors proceeded to the harvest procedure. Three donors randomised to PBPC collection and one potential bone marrow donor were not harvested; the reasons why they did not continue on the study protocol are detailed in Figure 1 .
Sixteen of 34 bone marrow donors (47%) and 22 of 36 PBPC donors (61%) experienced at least one adverse event of any severity. Table 2 lists all adverse events reported by the donors. One event in a marrow donor was considered severe by the investigator because anaemia detected after the donation (Hgb 10.4 g/dl) necessitated the transfusion of Table 1 Characteristics of donors and patients according to treatment group + cells/kg (CD34 + cells were not counted in the first of three apheresis products of the latter donor due to technical problems). Both grafts were used for transplantation and the patients engrafted with an ANC Ͼ0.5 × 10 9 /l reached on days 18 and 17; a platelet count Ͼ20 × 10 9 /l was reached on days 32 and 31, respectively. The cellular composition of 33 BM and PBPC harvests available for analysis is summarised in Table 3 .
Recipients
From January 1995 until May 1996 36 patients were randomised to PBPCT and 34 patients were randomised to Table 3 Characterisation of bone marrow (BM) and peripheral blood progenitor cell (PBPC) harvests 10 Two patients randomised to PBPCT actually were in relapse at the time of transplant; one BMT candidate was reported to be in unstable CR with a borderline blast count at the time of transplantation. Two patients with ALL in first remission given PBPC were Philadelphia chromosome positive, the other two ALL patients grafted in CR1 with BM or PBPC had normal karyotypes. All five ALL patients grafted in CR2 were cytogenetically normal. One recipient randomised to BMT and three recipients randomised to PBPCT were not treated according to the study protocol because of disease progression, relapse of the underlying disease, ineligibility of the donor, or because the donor requested a marrow harvest after randomisation to PBPCT. Thirty-three patients proceeded to each of PBPCT or BMT (see Figure 1 for details).
Conditioning therapy: Twenty-nine of 33 patients (88%) transplanted with BM and 27 of 33 patients (82%) transplanted with PBPC received a combination of TBI and chemotherapy. Four patients randomised to BMT (12%) and six patients randomised to PBPCT (18%) were given a combination of busulphan and cyclophosphamide. For further details see Table 4 .
Engraftment and hematopoietic recovery:
One patient died 14 days after BMT without hematopoietic recovery and six patients had not achieved a platelet count у50 × 10 9 /l at day +100 (end of the study) or until death on day +45 (one patient). All other patients who had received a marrow transplant were fully evaluable for neutrophil and platelet recovery. In the PBPCT arm, one patient died on day +25 without hematopoietic recovery; another patient died on day +32 and surpassed a neutrophil count of 0.5 × 10 9 /l on day +21 but failed to achieve an ANC Ͼ1.0 × 10 Table 4 Conditioning therapy for recipients of bone marrow or PBPC grafts Busulphan/CYCLO 4 6 FTBI = fractionated total body irradiation; STBI = single-dose TBI; CYCLO = cyclophosphamide. 
Graft-versus-host disease:
Twenty-seven of 33 patients in the BMT group (82%) and 31 of 33 patients in the PBPCT group (94%) received all three doses of MTX on days 1, 3 and 6; the remaining patients had only two MTX injections. The median number of days on CsA in the BMT or the PBPCT arm, respectively, was 100 (range: 14-100) and 100 (range: 19-100) days. The number of BM and PBPC recipients who experienced acute GVHD of grades 0-IV is given in Table 5 ; the probability of developing grade II-IV GVHD is depicted in Figure 4 . There were very few evaluable patients surviving 12 months or more after PBPCT or BMT, respectively. Of six patients grafted with allogeneic PBPC three were reported to suffer from extensive chronic GVHD and three did not. In the BMT arm two patients had developed limited chronic GVHD and four had no chronic GVHD.
Safety:
Severe toxicity as defined in the 'study endpoints and definitions' section is given in Table 6 . Overall, there were no differences between the treatment groups with respect to the feasibility and safety of BMT or PBPCT. Adverse events seen after both procedures were typical of patients undergoing allogeneic BMT. The median number Table 6 Summary of severe toxicities in patients transplanted with bone marrow or PBPC One patient in the PBPCT arm who died on day 101 is included.
of days with fever in patients transplanted with PBPC was 8 days (range: 0-55) compared to 13 days (range: 0-31) after BMT. The duration of the first hospital stay was 31 (range: 4-75) days after PBPCT and 35 (range: 2-84) days after BMT. The total number of days spent in hospital until end of study was 52 (range: 24-148) after PBPCT and 45 (range: 26-113) after BMT. Two patients in the BMT group and four patients in the PBPCT group died within 101 days post PBPCT. Transplant-related mortality for both groups of patients is graphically shown in Figure 5 .
Causes of death, relapse incidence, and leukaemia-free survival
As of 1 February 1997, 26 patients in the BMT arm and 24 patients in the PBPCT arm were alive at a median of 400 days (range: 261-740) after BMT and 401 days (range: 246-729) after PBPCT. Of 33 patients grafted with bone marrow, two died prior to day +100 and five additional patients had died by the time of the last follow-up. In the PBPCT group, four patients died before day +101 and five additional patients had died by the follow-up. The causes of death are summarised in Table 7 . Six patients relapsed after randomisation to PBPCT, one of them early after randomisation and before any study procedure had occurred. Five of these patients have already died, a patient with CML was alive with relapse at the time of last evaluation. Three of four patients who died of relapse after PBPCT had poor-risk acute leukaemias (see Table 7 ). One patient randomised to BMT relapsed prior to BMT and died. Two patients with AML or ALL transplanted with BM have relapsed 223 and 261 days after BMT, but were still alive at the time of last follow-up. Another patient grafted with BM cells relapsed 127 days after BMT, was given donor lymphocyte infusions for treatment of relapse and subsequently died of GVHD 322 days after BMT. Leukaemiafree survival for both transplant groups is given in Figure 6 . 
Discussion
This study evaluated the feasibility, safety, and clinical consequences of harvesting allogeneic PBPC or BM from normal individuals followed by the transplantation of such cells to HLA-identical siblings with early leukaemia. The acute side-effects of filgrastim administration and leukaphereses in the donors were very similar to that reported previously 11, 12 and mainly consisted of musculoskeletal pain, headache, fever or fever-associated symptoms, and increases of hepatic enzymes and lactate dehydrogenase. It was reassuring to note that central venous access was not necessary in any of the donors. This observation demonstrates that clinical judgement is adequate to determine whether a donor's peripheral veins will allow adequate blood flow for the collection of PBPC. All acute sideeffects of filgrastim administration and leukaphereses were fully reversible; long-term sequelae have not been reported so far. Clearly, longer follow-up of larger cohorts of donors will be necessary to detect late or rare consequences of these procedures. 13 International co-operation as to how best to achieve this goal is currently under discussion. 14 Although severe or life-threatening immediate side-effects of harvesting PBPC did not occur, the overall frequency (61%) of side-effects may seem relatively high. It needs to be stressed, however, that we prospectively scrutinised all donors for any side-effects possibly related to the harvest procedures. This may at least partly explain why almost two-thirds of the PBPC donors but also half of the BM donors reported side-effects from the collection of haematopoietic cells. In a retrospective analysis of a comparable cohort of 701 BM donors only 22% of the donors experienced complications with the most frequently reported being pain, hypotension, weakness, bleeding and fever. 15 PBPC donors reported fewer days with restricted activities and spent less days in hospital. We realise that different practices at the various institutions participating in the trial may have biased these findings. Nevertheless, this is an important observation which -if confirmed in future studies -could mean better acceptability and major cost savings of PBPC as compared to BM harvesting. Similar observations have been made when the collection of autologous PBPC and BM were compared.
16,17
The collection of haematopoietic stem cells from peripheral blood yielded higher numbers of nucleated cells, CD34
+ cells, CFU-GM, T lymphocytes, and NK cells. The absolute and relative differences between PBPC and BM harvests with respect to the number of CD34
+ cells and cells with GVHD-and graft-versus-leukaemia (GVL)-inducing potential (T cells, NK cells) were less pronounced, however, than reported earlier. 18, 19 This discrepancy may reflect the effects of the different doses of filgrastim used to mobilise PBPC or the varying blood volumes processed from individual donors; it could also be a consequence of the study protocol which specified that a second leukapheresis was to be performed only if the threshold dose of 4 × 10 6 CD34 + cells/kg was not met with the first leukapheresis procedure. Higher median cell yields would undoubtedly have been possible if two or more collections would have been performed in all donors. Such a policy, however, would not only have increased the number of CD34 + cells and potentially further accelerated haematopoietic recovery but also would have led to higher numbers of T and NK cells contaminating the grafts. Whether this would have caused a higher incidence of severe GVHD is an open question.
With the numbers of CD34 + cells and CFU-GM infused into the recipients of PBPC or BM studied here the transplantation of PBPC resulted in faster platelet and possibly also neutrophil recovery. Compared with the results of a randomised trial comparing autologous BMT and autologous PBPCT 20 which showed a difference of 7 days for platelet recovery (Ͼ20 × 10 9 /l) and 3 days for neutrophil recovery (ANC Ͼ0.5 × 10 9 /l), the differences observed in the allogeneic setting were less marked. This finding was not
